Psoriatic Arthritis

A study presented at ACR 2021 found that CBD had no significant effect on pain intensity in patients with hand osteoarthritis or psoriatic arthritis.

An assessment of data from the DISCOVER and VOYAGE trials show the IL-23 inhibitor provides similar safety profiles in patients with either psoriatic disease.

With the popularity of CBD growing in Denmark, Jonathan Vela, MD, examined the effectiveness of CBD treatment on hand osteoarthritis and psoriatic arthritis.

The oral selective inhibitor showed significant benefit versus placebo at 2 different doses in the phase 2b trial.

Laure Gossec, MD, PhD discusses the association between improvements in patient-reported outcomes and disease activity in patients with psoriatic arthritis.

Interview questions focused on mental and physical health, guidance received by healthcare providers, and the impact of COVID-19 on healthcare access and self-management behaviors.

The risk of adverse outcomes increased the most in pregnancies with antirheumatic treatment, especially those treated with biologic disease modifying antirheumatic drugs (bDMARDs), when compared with controls.

The rates of adverse events was similar across all 4 indications in comparison to the placebo group.

The study examines the impact of antirheumatic treatment on pregnancy outcomes in women with psoriatic arthritis.

A significant number of patients with psoriatic arthritis fail to achieve adequate disease control, resulting in health-related quality of life (HRQOL) impairments.

Dactylitis, a uniform swelling of an entire digit, occurs in up to half of patients with psoriatic arthritis and is sometimes the first manifestation of the condition.

“Evidence has accumulated on the effectiveness of physical activity to reduce disease-related symptoms such as pain and comorbidity risk in people with rheumatoid arthritis,” investigators stated.

The post hoc analyses evaluated health-related quality of life and efficacy across 4 subgroups treated with either ixekizumab or adalimumab.

Test-retest reliability for Health Assessment Questionnaire–Disability Index and 36-item Short Form Health Survey physical functioning domain in patients with psoriatic arthritis was judged to be good and reasonable, respectively.

Results show how patients with psoriatic arthritis prioritize their decisions when choosing medication.

The efficacy evaluation of golimumab is crucial for patients with psoriatic arthritis, particularly for treating skin manifestations and psoriasis symptoms.

Early diagnosis and treatment of psoriatic arthritis leads to better long-term outcomes. Despite this, most patients have significant diagnostic delays.

Investigators analyze the differences between SARS-CoV-2 testing and risk of infection.

Investigators found that patients who were not treated with biologic medications were at a significantly increased risk of developing psoriatic arthritis.

Alexis Ogdie-Beatty, MD, discusses the UPLIFT survey and UPLIFT Innovation Challenge, the unmet needs of patients with psoriatic arthritis, and the clinical significance of the survey’s results.

Compared with controls, patients with psoriatic arthritis presented more often with depression at baseline and patients with rheumatoid arthritis had a higher incidence of cardiovascular comorbidity after 3 years.

Philip J Mease, MD, discusses his study, “Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.”

In this Q&A, corresponding author Josef S Smolen, MD, discussed the findings of his study determining the effectiveness of ustekinumab versus tumor necrosis factor inhibition in patients with psoriatic arthritis.

Researchers record more depressive symptoms in patients with psoriatic arthritis, which they believe incentivizes doctors to utilize screening methods that focus on the mental health of a patient.

Guselkumab, an interleukin-23p19-subunit inhibitor, led to clinically significant and sustained improvements in fatigue through 1 year in patients with active psoriatic arthritis.